Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

617

Participants

Timeline

Start Date

January 31, 1991

Primary Completion Date

January 31, 1992

Study Completion Date

January 31, 1992

Conditions
Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational AgeInfant, PrematureBronchopulmonary Dysplasia
Interventions
DRUG

Exosurf

Infants received up to four intratracheal doses of the surfactant.

DRUG

Survanta

Infants received up to four intratracheal doses of the surfactant.

Trial Locations (13)

20052

George Washington University, Washington D.C.

30303

Emory University, Atlanta

33136

University of Miami, Miami

38163

University of Tennessee, Memphis

44106

Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland

45267

Cincinnati Children's Medical Center, Cincinnati

46202

Indiana University, Indianapolis

48201

Wayne State University, Detroit

75235

University of Texas Southwestern Medical Center at Dallas, Dallas

87131

University of New Mexico, Albuquerque

94304

Stanford University, Palo Alto

06504

Yale University, New Haven

05405

University of Vermont, Burlington

All Listed Sponsors
lead

NICHD Neonatal Research Network

NETWORK